BridgeMD
New treatment option for Ischemic Stroke
Official title Stroke-induced Myocardial Dysfunction: Role of GDF-15 (SMOG-15) Clinical Work Package
ClinicalTrials.gov ID: NCT05683873
What this study is testing
What is standard biology?
standard biology is an investigational medicine, being studied as a potential treatment for ischemic stroke.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The aim of this study is to analyze the relationship between the blood biomarker GDF-15 and heart damage after stroke. It is being conducted in France, in the Neurology Department of the Dijon University Hospital (Burgundy).
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Adult with acute symptomatic cerebral infarction documented by brain imaging on admission (cerebral angioscan or cerebral MRI)
- Whose first symptoms appeared within 24 hours before inclusion
- Whose consent to participate in this study was obtained from the patient or a close relative.
You likely can't join if
- Person with a history of symptomatic stroke, either ischemic or hemorrhagic
- Anyone with a history of heart disease including: atrial fibrillation or flutter (known or discovered on admission), chronic heart failure...
- Person with acute heart failure, suspected infective endocarditis, STEMI, or concurrent pulmonary embolism
- A person who is not a member or beneficiary of a social security system
- Person deprived of liberty
- Person subject to a legal protection measure (curatorship, guardianship)
See the full eligibility criteria
- Adult with acute symptomatic cerebral infarction documented by brain imaging on admission (cerebral angioscan or cerebral MRI)
- Whose first symptoms appeared within 24 hours before inclusion
- Whose consent to participate in this study was obtained from the patient or a close relative.
- Person with a history of symptomatic stroke, either ischemic or hemorrhagic
- Anyone with a history of heart disease including: atrial fibrillation or flutter (known or discovered on admission), chronic heart failure, pacemaker, defibrillator, or other cardiac devices
- Person with acute heart failure, suspected infective endocarditis, STEMI, or concurrent pulmonary embolism
- A person who is not a member or beneficiary of a social security system
- Person deprived of liberty
- Person subject to a legal protection measure (curatorship, guardianship)
- Person subject to a legal protection measure
- Pregnant, parturient or breastfeeding woman
The study team makes the final eligibility decision.
Where it's taking place
- Dijon, France
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Dijon, France. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.